Prostate cancer treatment cost in Spain typically starts with essential diagnostics like a PET/CT scan running $1,300 to $1,800. Common surgical interventions, such as a robotic da Vinci prostatectomy, range from $10,000 to $15,000. Total expenses depend on the cancer stage, chosen technology, and facility tier. Patients often find 30-50% savings compared to the US, with primary medical hubs located in Barcelona and Madrid.
Typical Prostate Cancer Treatment Costs in Spain
Bookimed Expert Insight: Early-stage patients benefit most from precision diagnostics and robotic surgery. Centro Médico Teknon offers comprehensive diagnostic packages for approximately $8,750, following Memorial Sloan Kettering guidelines. For advanced cases requiring specialized radiation, the Proton Therapy Centre Quironsalud provides cutting-edge treatment in Madrid. Patients seeking world-class expertise should consider Dr. Antonio Alcaraz, a global pioneer in robotic urological surgery at Hospital Quiron Barcelona.
| Turkey | Austria | Spain | |
| Transurethral resection of the prostate (TURP) | from $3,580 | from $5,500 | from $4,000 |
| Tomotherapy | from $7,150 | from $30,000 | from $35,000 |
| Robotic da Vinci prostatectomy | from $16,500 | from $20,000 | from $10,000 |
| Radiotherapy for prostate cancer | from $4,000 | from $14,000 | from $4,000 |
| Proton-beam therapy | from $70,000 | from $80,000 | from $25,434 |
Prof. Galceran leads Spain's Genitourinary Cancer Unit at Vall d'Hebron, specializing in prostate cancer with 900+ procedures and national clinical trials.
Prof. Miralbell performs over 120 radiotherapy courses annually at Centro Médico Teknon – a pioneer in high-precision prostate cancer treatment.
Dr. Antonio Alcaraz specializes in prostate cancer treatment, performing over 500 urogenital surgeries with minimally invasive techniques and the Da Vinci robotic system.
Dr. Enrique Grande, MD, PhD, MSc, is a medical oncologist with more than 20 years of experience. He is an international expert in genitourinary and neuroendocrine tumors. He directs the Medical Oncology Department and the One Oncology Madrid Cancer Program at QuirónSalud, Spain’s largest private healthcare network. He leads an integrated, multidisciplinary model with access to targeted therapies and clinical trials.
He is a pioneer in precision oncology. He uses molecular profiling and biomarker-based care. He has authored more than 300 peer-reviewed papers. He serves as a principal investigator and sits on steering committees for many international trials. These studies help set standards of care in urothelial bladder and neuroendocrine tumors. He contributes to guidelines and programs at ESMO, ASCO, ENETS, and EAU.
Written by Anna Leonova
Written by Olena Sikoza